home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 06/04/24

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - MRUS Price Target Alert: $88.00. Issued by Truist Financial

2024-06-04 09:00:06 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for MRUS on 2024-06-04 08:08:00. The adjusted price target was set to $88.00. At the time of the announcement, MRUS was trading at $52.94. The overall price target consensus...
MRUS - Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...

MRUS - Merus announces pricing of upsized public offering of common shares

2024-05-30 03:10:38 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...

MRUS - Merus Announces Pricing of Upsized Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...
MRUS - Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D....

MRUS - Buy Recommendation Issued On MRUS By Citigroup

2024-05-28 21:15:01 ET Citigroup analyst issues BUY recommendation for MRUS on May 28, 2024 08:02PM ET. The previous analyst recommendation was Buy. MRUS was trading at $54.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

MRUS - Merus announces proposed public offering of common shares

2024-05-28 16:12:04 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...
MRUS - MRUS Price Target Alert: $84.00. Issued by BMO Capital

2024-05-28 14:00:08 ET Etzer Darout from BMO Capital issued a price target of $84.00 for MRUS on 2024-05-28 11:51:00. The adjusted price target was set to $84.00. At the time of the announcement, MRUS was trading at $53.86. The overall price target consensus is at $61.75...

MRUS - MRUS Price Target Alert: $90.00. Issued by Stifel Nicolaus

2024-05-28 12:00:11 ET Bradley Canino from Stifel Nicolaus issued a price target of $90.00 for MRUS on 2024-05-28 10:25:00. The adjusted price target was set to $90.00. At the time of the announcement, MRUS was trading at $54.8. The overall price target consensus is at $...

MRUS - Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage onco...
Previous 10 Next 10